/Companies

Deuteroncology

Liege, BE · Founded 2022 · 101 employees on LinkedIn · 1 known investors

Find your way into Deuteroncology

Sign up to see every warm intro you have to Deuteroncology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Deuteroncology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.

Founders & leadership

Deuteroncology was founded in 2022 by Timothy Perera.

TP
Timothy PereraPhD Founder & CEOTimothy Perera holds a Ph.D. in Cell Biology and has over 30 years of experience in oncology drug development. He previously served as Chief Scientific Officer and Founder of OCTIMET Oncology, a company he spun out from Janssen Pharmaceuticals where he had been Senior Director of Oncology Discovery, and now leads DeuterOncology as Founder and CEO.

Investors · 1

Frequently asked questions

What does Deuteroncology do?
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
Who founded Deuteroncology?
Deuteroncology was founded by Timothy Perera in 2022.
Who are Deuteroncology's investors?
Deuteroncology's investors include Newton Biocapital.
Where is Deuteroncology headquartered?
Deuteroncology is headquartered in Liege, BE.